Journal
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
Volume 27, Issue 1, Pages 133-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.idc.2012.11.014
Keywords
Community-acquired infections; Pneumonia; Therapeutics; Intensive care unit
Categories
Funding
- Instituto de Salud Carlos III [BAE11/00102]
- Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR)
- Societat Catalana de Pneumologia (SOCAP)
- Fundacio Catalana de Pneumologia (FUCAP)
- National Heart, Lung, and Blood Institute [K23HL096054]
Ask authors/readers for more resources
Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the United States. The mortality rate due to severe CAP has shown little improvement over the past few years, with a rate as high as 50% mainly in patients admitted to intensive care units. Death and adverse outcomes from CAP result from a complex interplay between the pathogen and the host. Several therapies have been tested in patients with severe CAP in recent years. This article reviews recent data regarding different treatments including antimicrobials and adjunctive therapies in patients with severe CAP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
